These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 22895140

  • 1. Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial.
    Fink TH, Huber RM, Heigener DF, Eschbach C, Waller C, Steinhauer EU, Virchow JC, Eberhardt F, Schweisfurth H, Schroeder M, Ittel T, Hummler S, Banik N, Bogenrieder T, Acker T, Wolf M, “Aktion Bronchialkarzinom” (ABC Study Group).
    J Thorac Oncol; 2012 Sep; 7(9):1432-9. PubMed ID: 22895140
    [Abstract] [Full Text] [Related]

  • 2. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
    Eckardt JR, von Pawel J, Papai Z, Tomova A, Tzekova V, Crofts TE, Brannon S, Wissel P, Ross G.
    J Clin Oncol; 2006 May 01; 24(13):2044-51. PubMed ID: 16648504
    [Abstract] [Full Text] [Related]

  • 3. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K, Tanaka H, Takeda K, Nishio M, Mori K, Satouchi M, Hida T, Yoshimura N, Kozuki T, Imamura F, Kiura K, Okamoto H, Sawa T, Tamura T, JCOG0605 investigators.
    Lancet Oncol; 2016 Aug 01; 17(8):1147-1157. PubMed ID: 27312053
    [Abstract] [Full Text] [Related]

  • 4. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
    Ignatiadis M, Mavroudis D, Veslemes M, Boukovinas J, Syrigos K, Agelidou M, Agelidou A, Gerogianni A, Pavlakou G, Tselepatiotis E, Nikolakopoulos J, Georgoulias V.
    Clin Lung Cancer; 2005 Nov 01; 7(3):183-9. PubMed ID: 16354313
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease.
    Sorensen M, Lassen U, Jensen PB, Østerlind K, Jeppesen N, Jensen BB, Mellemgaard A, Rytter C, Langer SW.
    J Thorac Oncol; 2008 Aug 01; 3(8):902-6. PubMed ID: 18670309
    [Abstract] [Full Text] [Related]

  • 6. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
    Petrioli R, Roviello G, Laera L, Luzzi L, Paladini P, Ghiribelli C, Voltolini L, Martellucci I, Bianco V, Francini E.
    Clin Lung Cancer; 2015 Nov 01; 16(6):e229-34. PubMed ID: 26072097
    [Abstract] [Full Text] [Related]

  • 7. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
    Quoix E, Breton JL, Gervais R, Wilson J, Schramel F, Cardenal F, Ross G, Preston A, Lymboura M, Mattson K.
    Lung Cancer; 2005 Aug 01; 49(2):253-61. PubMed ID: 16022920
    [Abstract] [Full Text] [Related]

  • 8. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group.
    Schiller JH, Adak S, Cella D, DeVore RF, Johnson DH.
    J Clin Oncol; 2001 Apr 15; 19(8):2114-22. PubMed ID: 11304763
    [Abstract] [Full Text] [Related]

  • 9. Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.
    Baka S, Agelaki S, Kotsakis A, Veslemes M, Papakotoulas P, Agelidou M, Agelidou A, Tsaroucha E, Pavlakou G, Gerogianni A, Androulakis N, Vamvakas L, Kalbakis K, Mavroudis D, Georgoulias V.
    Anticancer Res; 2010 Jul 15; 30(7):3031-8. PubMed ID: 20683051
    [Abstract] [Full Text] [Related]

  • 10. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.
    O'Brien ME, Konopa K, Lorigan P, Bosquee L, Marshall E, Bustin F, Margerit S, Fink C, Stigt JA, Dingemans AM, Hasan B, Van Meerbeeck J, Baas P.
    Eur J Cancer; 2011 Oct 15; 47(15):2322-30. PubMed ID: 21684151
    [Abstract] [Full Text] [Related]

  • 11. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma.
    Tas F, Derin D, Guney N, Camlica H, Aydiner A, Topuz E.
    Lung Cancer; 2007 Jul 15; 57(1):79-83. PubMed ID: 17383768
    [Abstract] [Full Text] [Related]

  • 12. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.
    Mavroudis D, Veslemes M, Kouroussis Ch, Tzanakis N, Ferdoutsis E, Toumbis M, Ziotopoulos P, Agelidou M, Tselepatiotis E, Kalbakis K, Souglakos J, Magkanas E, Samonis G, Georgoulias V, Hellenic Oncology Research Group.
    Lung Cancer; 2002 Oct 15; 38(1):59-63. PubMed ID: 12367794
    [Abstract] [Full Text] [Related]

  • 13. Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study.
    Mavroudis D, Pavlakou G, Blazoyiannakis G, Veslemes M, Apostolopoulou F, Kouroussis Ch, Kakolyris S, Agelaki S, Androulakis N, Vardakis N, Magkanas E, Samonis G, Georgoulias V.
    Lung Cancer; 2003 Jan 15; 39(1):71-6. PubMed ID: 12499097
    [Abstract] [Full Text] [Related]

  • 14. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS, Wong H, Zee B, Yu KH, Leung TW, Lee TW, Yim A, Chan AT, Yeo W, Chak K, Johnson P.
    Cancer; 2002 Oct 01; 95(7):1511-9. PubMed ID: 12237920
    [Abstract] [Full Text] [Related]

  • 15. NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer.
    Ellis PM, Shepherd FA, Laurie SA, Goss GD, Olivo M, Powers J, Seymour L, Bradbury PA.
    J Thorac Oncol; 2014 Mar 01; 9(3):410-3. PubMed ID: 24518092
    [Abstract] [Full Text] [Related]

  • 16. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR, Hatfield AK, Hillman S, Bauman MD, Mailliard JA, Kugler JW, Morton RF, Marks RS, Levitt R.
    Cancer; 2003 May 15; 97(10):2498-503. PubMed ID: 12733149
    [Abstract] [Full Text] [Related]

  • 17. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A, Manegold C, Debruyne C, Gaafar R, Buchholz E, Smit EF, Lianes P, ten Velde G, Bosquee L, Legrand C, Neumaier C, King K, Giuseppe giaccone European organization for research and treatment of cancer (EORTC) lung cancer group.
    Clin Cancer Res; 2003 Jan 15; 9(1):143-50. PubMed ID: 12538462
    [Abstract] [Full Text] [Related]

  • 18. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
    Aisner J, Musanti R, Beers S, Smith S, Locsin S, Rubin EH.
    Clin Cancer Res; 2003 Jul 15; 9(7):2504-9. PubMed ID: 12855624
    [Abstract] [Full Text] [Related]

  • 19. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
    Lu C, Komaki R, Lee JS, Shin DM, Palmer JL, Coldman BJ, Pisters KM, Kurie JM, Fossella FV, Glisson BS.
    Clin Cancer Res; 2003 Jun 15; 9(6):2085-91. PubMed ID: 12796372
    [Abstract] [Full Text] [Related]

  • 20. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
    Reck M, Groth G, Buchholz E, Goetz E, Gatzemeier U, Manegold C.
    Lung Cancer; 2005 Jun 15; 48(3):409-13. PubMed ID: 15893010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.